Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.21/4932 |
Resumo: | The disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds I, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC <= 0.28 mu M), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (Le., 6.9 vs. 43.8 mu M). All compounds were ineffective against H37Rv(INH) (Delta katG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC. (C) 2014 Elsevier Masson SAS. All rights reserved. |
id |
RCAP_8ffcb1864c3787a5b95c641d642c30e1 |
---|---|
oai_identifier_str |
oai:repositorio.ipl.pt:10400.21/4932 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activityAntitubercular ActivityIsoniazid DerivativesMycobacterium TuberculosisResistanceQSARsSynthesisThe disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds I, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC <= 0.28 mu M), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (Le., 6.9 vs. 43.8 mu M). All compounds were ineffective against H37Rv(INH) (Delta katG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC. (C) 2014 Elsevier Masson SAS. All rights reserved.Elsevier France – Editions Scientifiques Medicales ElsevierRCIPLMartins, FilomenaSantos, SusanaVentura, CristinaElvas Leitao, RubenSantos, LídiaVitorino, SusanaReis, MarinaMiranda, VanessaCorreia, Henrique E.Aires-de-Sousa, JoãoKovalishyn, VasylLatino, Diogo A. R. S.Ramos, JorgeViveiros, Miguel2015-08-24T10:50:32Z2014-062014-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/4932engMARTINS, Filomena; [et al] – Design, synthesis and biologival evaluation of novel isoniazid derivaatives with potente antitubercular activity. European Journal of Medicinal Chemistry. ISSN: 0223-5234. Vol. 81 (2014), pp. 119-1380223-523410.1016/j.ejmech.2014.04.077metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T09:47:38Zoai:repositorio.ipl.pt:10400.21/4932Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:14:17.551830Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
title |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
spellingShingle |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity Martins, Filomena Antitubercular Activity Isoniazid Derivatives Mycobacterium Tuberculosis Resistance QSARs Synthesis |
title_short |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
title_full |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
title_fullStr |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
title_full_unstemmed |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
title_sort |
Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity |
author |
Martins, Filomena |
author_facet |
Martins, Filomena Santos, Susana Ventura, Cristina Elvas Leitao, Ruben Santos, Lídia Vitorino, Susana Reis, Marina Miranda, Vanessa Correia, Henrique E. Aires-de-Sousa, João Kovalishyn, Vasyl Latino, Diogo A. R. S. Ramos, Jorge Viveiros, Miguel |
author_role |
author |
author2 |
Santos, Susana Ventura, Cristina Elvas Leitao, Ruben Santos, Lídia Vitorino, Susana Reis, Marina Miranda, Vanessa Correia, Henrique E. Aires-de-Sousa, João Kovalishyn, Vasyl Latino, Diogo A. R. S. Ramos, Jorge Viveiros, Miguel |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
RCIPL |
dc.contributor.author.fl_str_mv |
Martins, Filomena Santos, Susana Ventura, Cristina Elvas Leitao, Ruben Santos, Lídia Vitorino, Susana Reis, Marina Miranda, Vanessa Correia, Henrique E. Aires-de-Sousa, João Kovalishyn, Vasyl Latino, Diogo A. R. S. Ramos, Jorge Viveiros, Miguel |
dc.subject.por.fl_str_mv |
Antitubercular Activity Isoniazid Derivatives Mycobacterium Tuberculosis Resistance QSARs Synthesis |
topic |
Antitubercular Activity Isoniazid Derivatives Mycobacterium Tuberculosis Resistance QSARs Synthesis |
description |
The disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds I, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC <= 0.28 mu M), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (Le., 6.9 vs. 43.8 mu M). All compounds were ineffective against H37Rv(INH) (Delta katG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC. (C) 2014 Elsevier Masson SAS. All rights reserved. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-06 2014-06-01T00:00:00Z 2015-08-24T10:50:32Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.21/4932 |
url |
http://hdl.handle.net/10400.21/4932 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
MARTINS, Filomena; [et al] – Design, synthesis and biologival evaluation of novel isoniazid derivaatives with potente antitubercular activity. European Journal of Medicinal Chemistry. ISSN: 0223-5234. Vol. 81 (2014), pp. 119-138 0223-5234 10.1016/j.ejmech.2014.04.077 |
dc.rights.driver.fl_str_mv |
metadata only access info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
metadata only access |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier France – Editions Scientifiques Medicales Elsevier |
publisher.none.fl_str_mv |
Elsevier France – Editions Scientifiques Medicales Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133400522555392 |